Health Care M&A Deals, November 20, 2020
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our HealthCareMandA.com Deal Database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week is CBPO Holdings Limited’s acquisition of China Biologic Products Holdings, Inc. (NASDAQ: CBPO) for $4.76 billion. Based in Beijing, China Biologic Products Holdings is a leading, fully integrated plasma-based biopharmaceutical company. The company’s products are used as critical therapies during medical emergencies and for the prevention... Read More » Health Care M&A Deals, November 13, 2020
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our HealthCareMandA.com Deal Database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week is Cano Health, LLC’s reverse merger with Jaws Acquisition Corp., a special purpose acquisition company. The deal is valued at $4.4 billion. Cano Health operates primary care centers and supports affiliated medical practices in Florida, Texas, Nevada, and Puerto Rico that specialize in value-based care for seniors. As part of its care... Read More » Health Care M&A Deals, November 6, 2020
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our HealthCareMandA.com Deal Database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week is Merck & Co., Inc.’s acquisition of VelosBio for $2.75 billion in cash. VelosBio is a privately held clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies. VelosBio’s lead investigational candidate, VLS-101, is currently being evaluated in a Phase 1 and a Phase 2 clinical trial for the treatment... Read More »
Diagnostics, COVID-19 and Beyond
Testing has become one of the most defining words of 2020, especially as it relates to the COVID-19 pandemic. We see it in headlines daily and President Trump lists the testing capacity of the United States as one of his crowning achievements. But politics and media coverage aside, health experts often cite testing as one of the key components to containing the spread of the virus, underscoring the importance of those services. The demand for COVID-19 testing and diagnostics can be seen in recent quarterly earnings reports. LabCorp’s (NYSE: LH) revenue jumped by 33% in Q3:20 to $3.9 billion, compared with Q3:19. Roughly 31.5% of the increase was thanks to organic growth, bolstered by... Read More » Health Care M&A Deals, October 30, 2020
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our HealthCareMandA.com Deal Database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week is Bayer AG’s acquisition of Asklepios BioPharmaceutical, Inc. for $2 billion upfront and a potential $2 billion in milestones. Asklepios BioPharmaceutical specializes in the research, development and manufacturing of gene therapies across different therapeutic areas, including investigational pre-clinical and clinical-stage candidates for the... Read More »